The company, Celgene UK, has informed NICE that they are unable to provide an evidence submission at this time and will work with us to reschedule. Therefore, we are suspending the appraisal whilst we consider the next steps.
Consequently the discussion of this appraisal at the committee meeting on the 8 July 2020 has been cancelled.
|
Status
|
Suspended
|
| Process |
STA 2018
|
| ID number |
1554
|
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Consultees
| Companies sponsors |
Celgene (luspatercept) |
| Others |
Department of Health and Social Care |
| |
NHS Bexley CCG |
| |
NHS England |
| |
NHS West London CCG |
| |
Welsh Government |
| Patient carer groups |
Black Health Agency |
| |
Blood Cancer UK |
| |
Equalities National Council |
| |
Genetic Alliance UK |
| |
Muslim Council of Britain |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
UK Thalassaemia Society |
| Professional groups |
British Blood Transfusion Society |
| |
British Society for Bone Marrow Transplantation (BSBMT) |
| |
British Committee for Standards in Haematology |
| |
British Society for Haematology |
| |
NHS Blood & Transplant |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
UK Clinical Pharmacy Association |
| |
UK Forum on Haemoglobin Disorders |
| |
UK Haemophilia Centre Doctors’ Organisation |
| |
UK National Screening Committee |
Commentators
| Assessment group |
Cochrane Haematological Malignancies Group |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |
| |
National Primary Care Research & Development Centre |
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Hospira UK (desferrioxamine) |
| |
Novartis Pharmaceuticals (desferrioxamine, deferasirox) |
| |
Swedish Orphan Biovitrum (deferiprone) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Hospital Information Services – Jehovah’s Witnesses |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |